UBS Group
CRSP icon

UBS Group’s CRISPR Therapeutics CRSP Stock Holding History

UBS Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,000
Closed -$2.59M – 10598
2025
Q3 		$2.59M Buy
+40,000
New +$2.3M ﹤0.01% 4706

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group's CRSP Position: Q1 2026 in Review

UBS Group reduced its CRISPR Therapeutics (CRSP) stake by 30% in Q1 2026, selling an estimated $40.2M and leaving 1,762,530 shares worth $83.8M. The position accounts for 0.01% of the portfolio, ranked #1191.

UBS Group first reported a position in CRSP in Q4 2016 and has held it in 38 quarters since. The position peaked at $152M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • UBS Group held 1,762,530 shares of CRISPR Therapeutics worth $83.8M as of Q1 2026.
  • UBS Group sold 761,614 CRISPR Therapeutics shares in Q1 2026, an estimated $40.2M.
  • CRISPR Therapeutics made up 0.01% of UBS Group's portfolio in Q1 2026, its #1191 holding.
  • UBS Group first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 38 quarters since.
  • UBS Group's CRISPR Therapeutics position peaked at $152M in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.